EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease

Domenico Tricò, Tongzhi Wu, Noemi Cimbalo, Martina Chiriacò, Cong Xie, Luca Sacchetta, Lorenzo Nesti, Simone Gallo, Lorenza Santoni, Maria C Masoni, Giovanni Petralli, Teresa V Fiorentino und 8 weitere

Diabetologia · 2026-07 · 69 (7) · 2073-2087

DOI: 10.1007/s00125-026-06730-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetologia, online erschienen am 21.04.2026. Verfasst von Domenico Tricò und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. domenico.trico@unipi.it. Hauptthemen laut MEDLINE: Glucose, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, National Health and Medical Research Council, Adelaide University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/hypothesis Hepatic glucose flux plays a crucial role in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), promoting de novo lipogenesis, inflammation and fibrosis. This study aimed to evaluate the kinetics of oral glucose absorption and one of its key modulators, gastric emptying, in individuals with early-stage MASLD vs matched control individuals.

Methods

We quantified glucose metabolic fluxes during a 75 g OGTT using stable isotopes in individuals with MASLD without fibrosis and in healthy control individuals. In a separate cohort, we measured the gastric emptying rate using the 13 C-acetate breath test during an OGTT and estimated hepatic steatosis risk.

Results

Compared with the control group, in the MASLD group the rate of appearance of oral ingested glucose (RaO) normalised to body weight was 34% higher at 1 h post-OGTT (+318±142 µmol/kg, p =0.031), resulting in a 52% increase in total glucose absorption (+6.4±1.8 g, p =0.001). Participants with MASLD exhibited reduced glucose clearance relative to plasma insulin levels but preserved post-load suppression of endogenous glucose production, indicating peripheral rather than hepatic insulin resistance. Among glucose metabolic fluxes, RaO showed the strongest association with prevalent MASLD, with each 1-SD increase in 1 h RaO being associated with fivefold higher odds of MASLD (OR 4.99 [95% CI 1.44, 31.57], p =0.036), independent of potential confounders. Gastric emptying rate was not associated with hepatic steatosis risk. Conclusions/interpretation Oral glucose absorption is augmented in individuals with MASLD without fibrosis, apparently unrelated to accelerated gastric emptying. This metabolic alteration may represent an early driver of MASLD pathogenesis, preceding hepatic insulin resistance. Future research should investigate whether modulation of intestinal glucose absorption confers therapeutic benefits in MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucoseFatty LiverHumansMaleFemaleGastric EmptyingMiddle AgedGlucose Tolerance TestAdultInsulin ResistanceBlood GlucoseInsulinLiver

Stichwörter der Autor:innen

Fatty liverGastric emptyingGlucose intoleranceInsulin resistanceIntestinal glucose absorptionObesitySodium–glucose cotransporterThe metabolic syndrome

Substanzen

GlucoseBlood GlucoseInsulin

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. domenico.trico@unipi.it.
  • Laboratory of Metabolism, Nutrition and Atherosclerosis, University of Pisa, Pisa, Italy. domenico.trico@unipi.it.
  • School of Medicine and Centre of Research Excellence in Translating Nutritional Science to Good Health, College of Health, Adelaide University, Adelaide, SA, Australia. tongzhi.wu@adelaide.edu.au.
  • Laboratory of Metabolism, Nutrition and Atherosclerosis, University of Pisa, Pisa, Italy.
  • Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Förderung

  • Ministero dell'Università e della Ricerca
  • National Health and Medical Research Council
  • Adelaide University

Zitieren

APA

Tricò, D., Wu, T., Cimbalo, N., Chiriacò, M., Xie, C., Sacchetta, L., Nesti, L., Gallo, S., Santoni, L., Masoni, M. C., Petralli, G., Fiorentino, T. V., Bizzotto, R., Scozzaro, M. T., Frascerra, S., Baldi, S., Brunetto, M. R., Mari, A., Rayner, C. K., & Natali, A. (2026). Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease. Diabetologia, 69(7), 2073-2087. https://doi.org/10.1007/s00125-026-06730-5

Vancouver

Tricò D, Wu T, Cimbalo N, Chiriacò M, Xie C, Sacchetta L, et al. Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease. Diabetologia. 2026;69(7):2073-2087. doi:10.1007/s00125-026-06730-5

BibTeX
@article{Tric2026,
  author = {Tricò, Domenico and Wu, Tongzhi and Cimbalo, Noemi and Chiriacò, Martina and Xie, Cong and Sacchetta, Luca and Nesti, Lorenzo and Gallo, Simone and Santoni, Lorenza and Masoni, Maria C and Petralli, Giovanni and Fiorentino, Teresa V and Bizzotto, Roberto and Scozzaro, Maria T and Frascerra, Silvia and Baldi, Simona and Brunetto, Maurizia R and Mari, Andrea and Rayner, Christopher K and Natali, Andrea},
  title = {Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease},
  journal = {Diabetologia},
  year = {2026},
  volume = {69},
  number = {7},
  pages = {2073--2087},
  doi = {10.1007/s00125-026-06730-5}
}
Kostenlos starten →